New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
04:55 EDTEBIO, EBIO, EBIO, EBIO, SURG, SURG, SURG, SURG, DNA, DNA, DNA, DNA, XOMA, XOMA, XOMA, XOMA, SQNM, SQNM, SQNM, SQNM, REGN, REGN, REGN, REGN, MRK, MRK, MRK, MRK, CAJ, CAJ, CAJ, CAJ, AGN, AGN, AGN, AGN, AGTC, AGTC, AGTC, AGTC, VRX, VRX, VRX, VRXAssociation for Research in Vision & Ophthalmology holds annual meeting
2014 Annual Meeting of ARVO is being held in Orlando, Florida on May 4-8.
News For EBIO;AGTC;AGN;CAJ;MRK;REGN;SQNM;XOMA;DNA;SURG;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 20, 2015
13:26 EDTVRXOn The Fly: Top stock stories at midday
Subscribe for More Information
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:20 EDTVRXOn The Fly: Pre-market Movers
Subscribe for More Information
09:13 EDTVRXPalatin up 15.18% after Valeant announces plans to buy Sprout for $1B
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
08:16 EDTAGNAllergan's Botox resubmission for lower limb spasticiy accepted by FDA
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
07:31 EDTVRXValeant to acquire Sprout Pharma for $1B, plus a share of future profits
Subscribe for More Information
05:50 EDTVRXValeant nears deal to buy Sprout Pharma for $1B, WSJ reports
Subscribe for More Information
August 19, 2015
18:34 EDTAGTCOn The Fly: After Hours Movers
Subscribe for More Information
17:46 EDTAGTCApplied Genetic says Biogen collaboration effective, equity investment closed
Subscribe for More Information
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information
August 17, 2015
06:22 EDTREGNPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
August 16, 2015
18:01 EDTVRXSenators question Valeant, Hospira on 'artifically inflated' drug prices
Subscribe for More Information
August 14, 2015
17:32 EDTAGNPershing Square gives quarterly update on stakes, liquidates Allergan position
Subscribe for More Information
17:08 EDTVRX, AGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
15:33 EDTAGNEndo confirms court ruling upholding OPANA ER intellectual property
Subscribe for More Information
14:15 EDTAGNEndo successful in blocking Opana generic until 2023, Bloomberg reports
Subscribe for More Information
08:35 EDTVRXHayman takes Mylan, Perrigo stakes, boasts exposure to energy
Subscribe for More Information
07:37 EDTAGNJANA reports new stakes in Allergan, TWC, sells Applied Materials
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use